These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 28740584)

  • 21. Cardiac abnormalities in acromegaly. Pathophysiology and implications for management.
    Vitale G; Pivonello R; Lombardi G; Colao A
    Treat Endocrinol; 2004; 3(5):309-18. PubMed ID: 15330678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of growth hormone in chronic heart failure: therapeutic implications.
    Volterrani M; Giustina A; Manelli F; Cicoira MA; Lorusso R; Giordano A
    Ital Heart J; 2000 Nov; 1(11):732-8. PubMed ID: 11110515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arterial pulse wave velocity, inflammatory markers, pathological GH and IGF states, cardiovascular and cerebrovascular disease.
    Graham MR; Evans P; Davies B; Baker JS
    Vasc Health Risk Manag; 2008; 4(6):1361-71. PubMed ID: 19337549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cardiovascular system in growth hormone excess and growth hormone deficiency.
    Lombardi G; Di Somma C; Grasso LF; Savanelli MC; Colao A; Pivonello R
    J Endocrinol Invest; 2012 Dec; 35(11):1021-9. PubMed ID: 23143695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Heart disease in acromegaly. Study of 27 patients].
    Marín F; Picó AM; Martínez JG; Domínguez JR; Alfayete R; Sogorb F
    Med Clin (Barc); 1996 Sep; 107(9):326-30. PubMed ID: 8984234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acromegaly and the cardiovascular system.
    Lombardi G; Galdiero M; Auriemma RS; Pivonello R; Colao A
    Neuroendocrinology; 2006; 83(3-4):211-7. PubMed ID: 17047385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced nitric oxide levels in acromegaly: cardiovascular implications.
    Ronconi V; Giacchetti G; Mariniello B; Camilletti A; Mantero F; Boscaro M; Vignini A; Mazzanti L
    Blood Press; 2005; 14(4):227-32. PubMed ID: 16126556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
    Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
    Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects.
    Colao A; Marzullo P; Spiezia S; Ferone D; Giaccio A; Cerbone G; Pivonello R; Di Somma C; Lombardi G
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1986-91. PubMed ID: 10372698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Acromegaly and it's cardiovascular implications].
    Cadena-Obando DA; Remba-Shapiro I; Abreu-Rosario CG; Mercado M
    Rev Med Inst Mex Seguro Soc; 2021 Feb; 59(1):73-80. PubMed ID: 33667046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The heart: an end-organ of GH action.
    Colao A; Vitale G; Pivonello R; Ciccarelli A; Di Somma C; Lombardi G
    Eur J Endocrinol; 2004 Aug; 151 Suppl 1():S93-101. PubMed ID: 15339252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors.
    Yaron M; Izkhakov E; Sack J; Azzam I; Osher E; Tordjman K; Stern N; Greenman Y
    Pituitary; 2016 Jun; 19(3):322-31. PubMed ID: 26873588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.
    Colao A; Ferone D; Marzullo P; Lombardi G
    Endocr Rev; 2004 Feb; 25(1):102-52. PubMed ID: 14769829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acromegaly, inflammation and cardiovascular disease: a review.
    Wolters TLC; Netea MG; Riksen NP; Hermus ARMM; Netea-Maier RT
    Rev Endocr Metab Disord; 2020 Dec; 21(4):547-568. PubMed ID: 32458292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.